MedPath

A Mild Supplementation of Arabinoxylan Fiber Improves Homa Index in Overweight and Obese Subjects.

Not Applicable
Conditions
Nutritional and Metabolic Diseases
Interventions
Dietary Supplement: Arabinoxylan Diet
Registration Number
NCT02847351
Lead Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Brief Summary

The study aimed to investigate whether an Arabinoxylan-enriched crackers consumption for 4 weeks in overweight and obese patients without diabetes mellitus have specific healthy effects on glycemic control (reduction of homeostatic model assessment -HOMA index-). Furthermore, study evaluated the effects of Arabinoxylan on insulin, lipid and Ghrelin.

Detailed Description

The beneficial effects of soluble dietary fiber to health are well known: many studies show clearly that it delays the onset of cardiovascular disease and some cancers, and improves glycemic control in type 2 diabetes. (1,2). Overweight and obesity are known to be associated with increased rate of diabetes, hypertension and cardiovascular diseases, as well as to colon and breast cancer. The introduction of 25-30gr of dietary fiber daily would therefore indicated not only in type 2 diabetic subjects, but also in obese and overweight patients. Most of the foods commonly consumed in Western countries are low in dietary fiber: to reach the recommended levels people should introduce whole grain cereals, legumes, vegetables and dried fruits, not always accepted. We tested the effects on health of crackers baked with a special Integralbianco® flour, enriched with 3,2g of Arabinoxylan / 100g (vs refined flour).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
19
Inclusion Criteria
  • males and females
  • age ≥ 18 years
  • Body mass Index ≥ 27
Exclusion Criteria
  • diabetes mellitus
  • already established organ damage
  • debilitating diseases

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Arabinoxylan Diet (AXD)Arabinoxylan DietPeriod 1(the first 4 weeks): 9 subjects were randomly assigned to Arabinoxylan-Diet: they replaced for 4 weeks all the carbohydrates consumed in day with crackers baked with an Arabinoxylan-enriched flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day with crackers produced with a normal white grain flour
Control Diet (CD)Arabinoxylan DietPeriod 1(the first 4 weeks): 10 subjects were randomly assigned to Control Diet: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with a normal white grain flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with Arabinoxylan-enriched flour.
Primary Outcome Measures
NameTimeMethod
Reduction of Homa Index after Ax Diet vs CD Diet4 weeks of arabinoxylan dietetic supplementation

The study aimed to investigate whether an Arabinoxylan enriched crackers consumption for 4 weeks in overweight or obese patients without diabetes mellitus have specific healthy effects on glycemic control, evaluated as reduction of Homa Index.

Secondary Outcome Measures
NameTimeMethod
Improvement of lipidic profile after AxDiet vs CD Diet4 weeks of arabinoxylan dietetic supplementation

The study aimed to investigate whether an Arabinoxylan enriched crackers consumption for 4 weeks had some benefic effects on lipids.

Improvement of weight after AxDiet vs CD Diet4 weeks of arabinoxylan dietetic supplementation

We investigate whether an Arabinoxylan enriched crackers consumption for 4 weeks had some effects on weight loss in obese or overweight subjects.

Trial Locations

Locations (2)

IRCCS Policlinico San Matteo Foundation

🇮🇹

Pavia, Italy

Internal Medicine Department, Clinica Medica II, IRCCS San Matteo Foundation

🇮🇹

Pavia, PV, Italy

© Copyright 2025. All Rights Reserved by MedPath